Atlas Trials

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Clinical trial NCT02143635 · COMPLETED

Trial details

NCT number
NCT02143635
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid and Hematological TP53wt Tumors
Start date
2014-07-07
Primary completion
2017-06-20
Enrollment
208

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.